Abstract 569P
Background
Artificial intelligence (AI) algorithms have been developed to distinguish MMR-D from MMR-P (proficient) tumors, yet they lack biological interpretability. To address this shortcoming, we used validated AI algorithms to detect and quantify well described morphological features in colon cancers from whole slide images.
Methods
Digital images of stage III colon carcinomas from participants in a phase III trial of FOLFOX-based adjuvant chemotherapy (NCCTG N0147; Alliance) were utilized. Available MMR-D (n=191) and randomly selected MMR-P (n=188) cancers were analyzed. QuantCRC quantifies the amount of stroma and stromal subtypes (immature, mature, inflammatory) and tumor/stroma ratio in addition to grade, mucin, signet ring cells, budding/poorly differentiated clusters (TB/PDC) and tumor-infiltrating lymphocytes (TILs). We also distinguished TILs in epithelium vs stromal using another AI algorithm (Lunit SCOPE IO). Area under the curve (AUC), i.e., discrimination threshold, was measured for each feature to predict MMR status.
Results
Among AI-derived morphological features, significant differences were found by MMR status whereby dMMR cancers had lower immature stroma but higher inflammatory stroma, higher tumor grade, and increased mucin, signet ring cells, tumor size, TB/PDCs, and TILs (all Kruskal-Wallis p<0.05). Univariately, AUC (95% CI) values for prediction of MMR status above 0.6 were as follows: TILs 0.72 (0.67-0.77), immature stroma 0.67 (0.62-0.73); inflammatory stroma 0.67 (0.62-0.73); tumor grade 0.65 (0.60-0.71); signet ring cells 0.65 (0.60-0.71); mucin 0.64 (0.59-0.70). Given that TILs in the overall tumor was most discriminant, we then utilized a TIL-specific AI algorithm measuring TILs in epithelium and stroma and found that epithelial TILs had a significantly higher AUC [ 0.79 (0.74-0.84) compared to stromal TILs 0.58 (0.52-0.63) p<0.0001].
Conclusions
Among morphological tumor features quantified by AI, tumor immature desmoplastic stroma and TILs, particularly epithelial TIL densities, were best able to distinguish MMR-D from MMR-P tumors. These findings have implications for prognosis and subtype-based interventions and can guide spatial molecular interrogation.
Clinical trial identification
NCT00079274.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Supported by Institutional grant support. NIH U10CA180821, U10CA180882, U24CA196171, R01 CA210509 (to FAS). Study NCCTG N0147 received funds from Sanofi.
Disclosure
G. Park, Y. Lim: Financial Interests, Institutional, Member: Lunit. D. Yan, K. Shanmugam: Financial Interests, Institutional, Full or part-time Employment: Roche. C-Y. Ock: Financial Interests, Institutional, Member: Lunit. All other authors have declared no conflicts of interest.
Resources from the same session
538P - Single-center retrospective analysis of patients with brain metastases included in early phase clinical trials
Presenter: Giulia Pretelli
Session: Poster session 10
539P - Epidemiology and prognostic factors of lung cancer and brain metastases: A 10-year retrospective population cohort study in Girona, Spain
Presenter: Eduard Teixidor Vilà
Session: Poster session 10
540P - Impact of adjuvant radiotherapy (ART) on survival time in patients with hemangiopericytoma (HPC): A population study
Presenter: Tala Alshwayyat
Session: Poster session 10
541P - A multicenter study evaluating the clinical and molecular characteristics of adult patients with diffuse midline and non-midline K27M altered gliomas
Presenter: Manuel Mazariegos Rubi
Session: Poster session 10
542P - Drug screening in Li-Fraumeni syndrome brain tumor models
Presenter: Anna Kolodziejczak
Session: Poster session 10
543P - Bevacizumab and hydroxyurea treatment in grade 2 and 3 meningioma: A monocentric experience
Presenter: Giulia Cerretti
Session: Poster session 10
544P - Clinical and molecular features of primary central nervous system tumor with Lynch syndrome
Presenter: Nan Liu
Session: Poster session 10
545P - Antibody-fragment based immunotherapeutic approaches for medulloblastoma and rhabdomyosarcoma
Presenter: Judith Niesen
Session: Poster session 10
546P - Early urinary potassium level is predictive of delayed methotrexate (MTX) elimination in patients with primary central nervous system lymphoma (PCNSL)
Presenter: Alexandre Bertucci
Session: Poster session 10
547P - Clinicopathological and molecular study of embryonal tumours with multilayered rosettes
Presenter: Lianghong Teng
Session: Poster session 10